19:28 , Jan 17, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of active, ligand-bound KOR could guide the design of biased KOR agonists to treat pain. A complex of crystallized KOR and a high-affinity ligand was suspended in a lipid-containing solution...
23:03 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology; dermatology

INDICATION: Pain; itch Mouse and rat studies suggest a G protein-biased KOR agonist could help treat pain and itch without the sedation and dysphoria caused by unbiased KOR agonists. A previously reported triazole-based, biased KOR...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: κ opioid receptor (KOR; OPRK1)

Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest KOR agonists could help treat MS. In co-cultures of neurons and oligodendrocyte precursor cells (OPCs), a KOR agonist tool compound increased differentiation of OPCs...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Asimadoline: Phase II started

Tioga began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 5 mg oral asimadoline daily for up to 8 weeks in about 200 patients. Tioga Pharmaceuticals Inc. , San Diego, Calif.   Product: Asimadoline...
08:00 , Feb 10, 2014 |  BioCentury  |  Product Development

Furiex's run at IBS-D

While Furiex Pharmaceuticals Inc. has hit its marks in two Phase III studies of eluxadoline to treat diarrhea-predominant irritable bowel syndrome, it is hard to say how the response rates measure up to the only...
07:00 , Mar 18, 2013 |  BioCentury  |  Emerging Company Profile

gIcare: Colonoscopy comfort

gIcare pharma Inc. is developing a pipeline of non-sedating colonic analgesic compounds to provide new and lower cost alternatives for pain management during colonoscopy. Sedation during endoscopy has become routine practice among gastroenterologists, even though...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that...
08:00 , Dec 24, 2012 |  BioCentury  |  Emerging Company Profile

Aros: Easing IBS pain

Aros Pharma ApS has found a new way to treat pain associated with irritable bowel syndrome. The company is developing an ASIC1A antagonist that specifically reduces gastrointestinal pain and could be an effective adjunct therapy...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

Asimadoline: Phase II started

Ono disclosed in its 1Q12 earnings ending June 30 that it began a double-blind, placebo-controlled, Japanese Phase II trial to evaluate oral asimadoline in about 189 patients. Ono has right to the compound from Tioga...
00:07 , Apr 13, 2012 |  BC Extra  |  Financial News

Tioga raises $10 million in series B

Tioga Pharmaceuticals Inc. (San Diego, Calif.) raised $10 million in a series B round led by new investor Thomas, McNerney & Partners. Existing investor Genesys Capital Partners also participated. Tioga's asimadoline is in the first...